CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers.

Concomitant strong or moderate CYP3A inducers: Avoid use with Nurtec ODT; may lead to loss of efficacy. Concomitant potent inhibitors of P-gp: Avoid another dose of Nurtec ODT within 48 hours.

Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response.

Beyond the liver risks, the warnings and precautions section of the prescribing information includes notes about hypersensitivity reactions, reduced effectiveness in patients on CYP3A inducers ...

See Contraindications. Concomitant moderate CYP3A inducers: not recommended. May be potentiated by combined P-gp, UGT1A1, and strong CYP3A inhibitors: concomitant use is not recommended.